IDBS’ Post

This morning, Lonza reported its Half-Year 2024 results. In Biologics, we delivered continued robust sales growth of 6.5% (7.3% CER) versus H1 2023, corresponding to mid-teens sales growth when excluding COVID-related mRNA sales in the prior year period. We saw continued strong demand for large-scale in our Mammalian business, and our agreement to acquire the Genentech Vacaville (US) site - which will extend our large-scale offering - is expected to close in Q4 2024. In Bioconjugates, sales were driven by strong commercial demand and interest in our strengthened ADC offering following the Synaffix acquisition.   Read more here: https://lnkd.in/d3ny7zq7   #AHealthierWorld #FinancialResults #Biologics

🚀💡 Exciting news in biopharma! Biovian and 3P Biopharmaceuticals unite forces to create 3PBIOVIAN, a top-tier pan-European biologics CDMO. Backed by Keensight Capital, the combined group offers end-to-end development and manufacturing services, targeting global biopharma clients. 💫 Dámaso Molero Sánchez, CEO at 3PBIOVIAN said: "The combination of technology, capabilities and most importantly, the quality of the human team, position us a leader in the highly dynamic international market for the development and manufacturing of advanced therapies. Together, we will be able to unleash the enormous potential for growth and value generation that we have accumulated over the years". Antti Nieminen, Deputy CEO at 3PBIOVIAN, added: “We are thrilled about this opportunity and the new chapter for our combined companies. The highly synergistic and comprehensive service offering allows 3PBIOVIAN to further enhance its competitiveness in the biologics CDMO market. The consolidation of these two technically and financially strong players creates a powerful global end-to-end service provider”. 🌍💉 With a wealth of combined expertise, 3PBIOVIAN is poised to bring unparalleled know-how to the market, revolutionizing the future of drug development. Follow 3PBIOVIAN on LinkedIn and visit our new homepage! Link available in the comments. 🔗 #3PBIOVIAN #3P #BIOVIAN #KeensightCapital #Biopharma #Biopharmaceuticals #CDMO

🚀💡 Exciting news in biopharma! Biovian and 3P Biopharmaceuticals unite forces to create 3PBIOVIAN, a top-tier pan-European biologics CDMO. Backed by Keensight Capital, the combined group offers end-to-end development and manufacturing services, targeting global biopharma clients. 💫 Dámaso Molero Sánchez, CEO at 3PBIOVIAN said: "The combination of technology, capabilities and most importantly, the quality of the human team, position us a leader in the highly dynamic international market for the development and manufacturing of advanced therapies. Together, we will be able to unleash the enormous potential for growth and value generation that we have accumulated over the years". Antti Nieminen, Deputy CEO at 3PBIOVIAN, added: “We are thrilled about this opportunity and the new chapter for our combined companies. The highly synergistic and comprehensive service offering allows 3PBIOVIAN to further enhance its competitiveness in the biologics CDMO market. The consolidation of these two technically and financially strong players creates a powerful global end-to-end service provider”. 🌍💉 With a wealth of combined expertise, 3PBIOVIAN is poised to bring unparalleled know-how to the market, revolutionizing the future of drug development. Follow 3PBIOVIAN on LinkedIn and visit our new homepage! Link available in the comments. 🔗 #3PBIOVIAN #3P #BIOVIAN #KeensightCapital #Biopharma #Biopharmaceuticals #CDMO

Watch Now! In our latest episode of Enzene Insights our Senior General Manager, and Head of Purification, Abijar Bhori shares insights on "Beyond Fed-Batch: The Age of Efficiency and Innovation Using Continuous Manufacturing for Biologics". He highlights the following key points: ➢How Enzene’s fully-connected continuous manufacturing (FCCM) resolves the stability issues in complex biologics like bispecifics, ADCs, and Fc-fusion proteins. ➢A case study demonstrating an 8 fold increase in productivity using FCCM for a bispecific interleukin molecule. ➢The future of biologics manufacturing and how FCCM drives innovation and efficiency in the field. and more... #EnzeneInsights #biologics #ContinuousManufacturing #drugmanufacturing

#Biopharmaceuticals_Contract_Manufacturing Market Projected to Deliver Greater Revenues during the Forecast Period >>https://lnkd.in/gmp7AGj3 #Biopharmaceuticals contract manufacturing is an approach where an #organization serves several other #pharmaceutical #industry companies by providing comprehensives services from #drug development through drug #manufacturing on a contractual basis. Boehringer Ingelheim, Lonza, Inno Biologics Sdn Bhd, Rentschler Biopharma, JRS PHARMA, AGC Biologics, ProBioGen AG, FUJIFILM Diosynth Biotechnologies, Toyobo U.S.A., Inc.., Samsung Biologics, Thermo Fisher Scientific, Binex Co.,ltd., WuXi Biologics, AbbVie #drugs #biologics  #operations #recombinant #health

🚀💡 Exciting News in Biopharma! Biovian and 3P Biopharmaceuticals unite forces to create 3PBIOVIAN, a top-tier pan-European biologics CDMO. Backed by Keensight Capital, the combined group offers end-to-end development and manufacturing services, targeting global biopharma clients.   Dámaso Molero Sánchez, CEO at 3PBIOVIAN said: "The combination of technology, capabilities and most importantly, the quality of the human team, positions us a leader in the highly dynamic international market for the development and manufacturing of advanced therapies. Together, we will be able to unleash the enormous potential for growth and value generation that we have accumulated over the years".   Antti Nieminen, Deputy CEO at Biovian, added: “We are thrilled about this opportunity and the new chapter for our combined companies. The highly synergistic and comprehensive service offering allows 3PBIOVIAN to further enhance its competitiveness in the biologics CDMO market. The consolidation of these two technically and financially strong players creates a powerful global end-to-end service provider”.    🌍💉 With a wealth of combined expertise, 3PBIOVIAN is poised to bring unparalleled know-how to the market, revolutionizing the future of drug development.   Links for press release and homepage are available in the comments! 🔗   #3PBIOVIAN #3P #BIOVIAN #Biopharma #Biopharmaceuticals #CDMO

In AGC Biologics' most recent blog, we discuss strategic approaches for successful cell line development. Learn how early engagement and collaboration with CDMOs streamline processes, while we delve into key variables like productivity and scalability. Read the full blog to explore the future of the industry and the pivotal role of CDMOs in CLD trends: https://lnkd.in/gpXW5Etp #biotech #pharma #Biopharma #pharmaceuticals #LifeScience #Biotechnology #celltherapy #genetherapy #viralvector #Biopharmaceuticals #AGCBio #CDMO

Looking forward to giving a talk on "....Challenges in Patenting biologics, biosimilars, and bispecific antibodies" at the LSPN (Life Sciences Patent Network) conference in San Francisco tomorrow. #biologics, #biotechnology, #patents, #biosimilars, #bispecific antibodies, #antibodies, #antibody formulations.

Want to know what NanoSyrinx does in (somewhat) plain language? Want to know why pharma is so interested in biologics? Want to know why delivering them is such a pain? Read on! https://lnkd.in/gbfT_Geu #syntheticbiology #synbio #drugdelivery #biologics #celltrends

Please watch Abijar's video with his insights how Enzene's fully connected continuous process has drastically improved the yield and purity of bi-specific antibodies as well as regular mAbs.